Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has experienced a rise in its stock price by 1.86 compared to its previous closing price of 27.94. However, the company has seen a fall of -1.83% in its stock price over the last five trading days. businesswire.com reported 2025-04-08 that PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evaluating the safety and effectiveness of ZYN002 in children, adolescents, and adults with Fragile X syndrome (FXS). The data showed clinically meaningful improvements in irritability-related symptoms prevalent in individuals with FXS. There are currently no U.S. Food & Drug Administration (FDA) ap.
Is It Worth Investing in Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Right Now?
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has a higher price-to-earnings ratio of 11.34x compared to its average ratio. HRMY has 36-month beta value of 0.86. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HRMY is 43.54M, and currently, short sellers hold a 8.02% ratio of that float. The average trading volume of HRMY on April 18, 2025 was 710.12K shares.
HRMY’s Market Performance
The stock of Harmony Biosciences Holdings Inc (HRMY) has seen a -1.83% decrease in the past week, with a -17.27% drop in the past month, and a -26.15% fall in the past quarter. The volatility ratio for the week is 4.46%, and the volatility levels for the past 30 days are at 4.73% for HRMY. The simple moving average for the past 20 days is -8.06% for HRMY’s stock, with a -18.11% simple moving average for the past 200 days.
Analysts’ Opinion of HRMY
Many brokerage firms have already submitted their reports for HRMY stocks, with Deutsche Bank repeating the rating for HRMY by listing it as a “Buy.” The predicted price for HRMY in the upcoming period, according to Deutsche Bank is $55 based on the research report published on February 11, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see HRMY reach a price target of $75. The rating they have provided for HRMY stocks is “Buy” according to the report published on December 17th, 2024.
HRMY Trading at -14.97% from the 50-Day Moving Average
After a stumble in the market that brought HRMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.60% of loss for the given period.
Volatility was left at 4.73%, however, over the last 30 days, the volatility rate increased by 4.46%, as shares sank -18.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.69% lower at present.
During the last 5 trading sessions, HRMY fell by -1.83%, which changed the moving average for the period of 200-days by -6.44% in comparison to the 20-day moving average, which settled at $30.95. In addition, Harmony Biosciences Holdings Inc saw -17.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HRMY starting from Kapadia Sandip, who sale 6,987 shares at the price of $32.54 back on Apr 01 ’25. After this action, Kapadia Sandip now owns 0 shares of Harmony Biosciences Holdings Inc, valued at $227,386 using the latest closing price.
SANDIP KAPADIA, the Officer of Harmony Biosciences Holdings Inc, proposed sale 6,986 shares at $33.19 during a trade that took place back on Apr 01 ’25, which means that SANDIP KAPADIA is holding shares at $231,865 based on the most recent closing price.
Stock Fundamentals for HRMY
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.76 for the gross margin
The net margin for Harmony Biosciences Holdings Inc stands at 0.2. The total capital return value is set at 0.23. Equity return is now at value 25.84, with 16.07 for asset returns.
Based on Harmony Biosciences Holdings Inc (HRMY), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 13.53. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 10.91.
Currently, EBITDA for the company is 233.41 million with net debt to EBITDA at -1.95. When we switch over and look at the enterprise to sales, we see a ratio of 1.67. The receivables turnover for the company is 8.61for trailing twelve months and the total asset turnover is 0.72. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.31.
Conclusion
To put it simply, Harmony Biosciences Holdings Inc (HRMY) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
